SILENCE THERAP. SP.ADR/1 (XRP2) — Strategic Asset Allocation Index
SILENCE THERAP. SP.ADR/1 (XRP2) has a Strategic Asset Allocation Index of 0.3% as of September 2024. Strategic assets (PP&E of €- plus long-term investments of €380.05K) total €380.05K, measured against net assets of €126.48 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
SILENCE THERAP. SP.ADR/1 Strategic Asset Allocation Index (2021–2023)
This chart shows how SILENCE THERAP. SP.ADR/1's Strategic Asset Allocation Index has evolved across 3 annual periods from 2021 to 2023. As of September 2024, the index stands at 0.3%, representing strategic assets of €380.05K against net assets of €126.48 Million EUR. Explore XRP2 cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for SILENCE THERAP. SP.ADR/1 (2021–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for SILENCE THERAP. SP.ADR/1 from 2021 to 2023, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see SILENCE THERAP. SP.ADR/1 market capitalisation.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 1.6% | €361.79K | €- | €361.79K | €21.99 Million | ▲ +0.4 pp |
| 2022 | 1.3% | €343.70K | €- | €343.70K | €26.71 Million | ▼ -2.2 pp |
| 2021 | 3.5% | €406.24K | €- | €406.24K | €11.51 Million | — |